Zai Lab Announces Upcoming Presentations at June Investor Conferences
05/24/2022 - 07:30 AM
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following investor conferences in June:
Jefferies Global Healthcare Conference 2022 Presentation: Thursday, June 9, 2022, 9:00 a.m. ET
Goldman Sachs 43rd Annual Global Healthcare Conference Fireside Chat: Thursday, June 16, 2022, 9:20 a.m. PT
Webcast links of the conferences will be available under “Events & Presentations” in the “Investor Relations” section of Zai Lab’s website. An archived replay will be viewable after the presentation for the following 90 days.
About Zai Lab
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is a patient-focused, innovative, commercial-stage, global biopharmaceutical company focused on developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. To that end, our experienced team has secured partnerships with leading global biopharmaceutical companies to generate a broad pipeline of innovative marketed products and product candidates. We have also built an in-house team with strong product discovery and translational research capabilities and are establishing a pipeline of proprietary product candidates with global rights. Our vision is to become a leading global biopharmaceutical company, discovering, developing, manufacturing, and commercializing our portfolio to impact human health worldwide.
For additional information about Zai Lab, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global .
For more information, please contact:
ZAI LAB CONTACTS:
Investor Relations: Lina Zhang +86 136 8257 6943lina.zhang@zailaboratory.com Media: Danielle Halstrom / Xiaoyu Chen +1 (215) 280-3898 / +86 185 0015 5011danielle.halstrom@zailaboratory.com / xiaoyu.chen@zailaboratory.com
Zai Lab Limited
Source: Zai Lab Limited
ZLAB Rankings
#1648 Ranked by Stock Gains
ZLAB Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
China (Mainland)
City
Shanghai
About ZLAB
zai lab is a biopharmaceutical company dedicated to discovering, developing and commercializing innovative medicines. our vision is to address the largest unmet medical needs and transform patients’ lives around the world. we take a unique approach to combine both in-licensed products and internal r&d; to achieve a rich pipeline. we believe our drug candidates can be truly disease modifying and bring significant benefits to patients. the company was founded in 2013 by a group of industry veterans. the founders are known as pioneers in china’s fast advancing biotech industry with a proven track record for successful chinese cfda and us fda filings and approvals. our senior management team introduced fast regulatory approval pathways in china and developed a variety of partnership models with multinational pharmaceutical companies. we endeavor to conduct world class clinical development in china and beyond. zai lab has strong backing from a leading group of healthcare investors. our inve